Tag:
BL-1040
Latest Headlines
Latest Headlines
Ikaria inks $285M pact for heart attack therapy
Israel's BiolineRx has licensed its early-stage BL-1040 heart attack therapy to Ikaria for $285 million in upfront fees and milestones. But Israel's chief scientist will have to sign off on the pact
